00:21 , May 3, 2019 |  BC Innovations  |  Product Development

With a deal and a debut, targeted oligo delivery gets a boost from ADCs

The marriage of antibody-drug conjugates and oligonucleotides won two votes of confidence last month with a deal between Lilly and Avidity, and the debut of Atlas-backed Dyne Therapeutics. The approach promises delivery of oligos to...
14:31 , Apr 26, 2019 |  BC Extra  |  Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...
20:04 , Apr 25, 2019 |  BC Innovations  |  Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for...
00:24 , Apr 12, 2019 |  BC Innovations  |  Product Development

NLRP3 early and often

Inflammasome inhibitors could offer a step change for a slew of inflammatory diseases and pharma is taking notice. Two acquisitions in six months show the first inflammasome target -- NLRP3 -- is gaining momentum, but...
17:11 , Apr 5, 2019 |  BC Week In Review  |  Company News

Atlas' build-to-buy Arteaus sells Emgality royalties for $260M

Arteaus sold its royalty rights for Lilly's Emgality galcanezumab-gnlm to Royalty Pharma (New York, N.Y.) for $260 million. Atlas Ventures and OrbiMed Advisors launched Arteaus Therapeutics LLC in October 2011 with $18 million to develop...
20:52 , Apr 3, 2019 |  BC Extra  |  Financial News

Rare muscle disease start-up Dyne raises $50M series A

Founded and incubated by Atlas Venture, newly launched Dyne Therapeutics Inc. (Cambridge, Mass.) announced a $50 million series A round with which it intends to develop therapies that deliver oligonucleotides directly into muscle to treat...
10:30 , Apr 3, 2019 |  BioCentury  |  Finance

The dynamics of Dyne

Incubated by Atlas Venture and launched Wednesday with a $50 million series A round, Dyne Therapeutics Inc. is using its muscle-targeting platform to develop therapies for rare diseases, beginning with myotonic dystrophy type 1 (DM1)....
05:15 , Apr 1, 2019 |  BC Extra  |  Company News

Novartis buying IFM inflammasome unit less than a year after launch

Novartis will pay $310 million up front to acquire IFM Tre and its trio of NLRP3 antagonists. Shareholders of the inflammatory disease subsidiary are also eligible for up to $1.3 billion in milestones. IFM Therapeutics...
23:07 , Mar 20, 2019 |  BioCentury  |  Finance

Flagship prepares for scale

With its newly closed $824 million Special Opportunities Fund II, Flagship Pioneering has deepened its pool of capital to invest in its portfolio companies as they seek to scale up with multiproduct platforms. Upon the...
01:17 , Feb 16, 2019 |  BC Extra  |  Company News

Emerging company roundup: Passage, IFM, Grey Wolf, Culture

In a week that had a pair of innovative Chinese companies raise early venture rounds and a Bay Area company debut its digital biomanufacturing platform, the biggest series A round went to Philadelphia gene therapy...